Skip to content

Released Feb 25, 2025, before the open

10-K filed Feb 25, 2025, 56 days after period end · 0000950170-25-026066

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$215.66Mderived+7.6% vs Q4 2023+9.7% vs Q3 2024
Net Income-$29.15MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$148,841,000+8.9%
Operating Incomederived-$11,477,000N/M
Operating Cash Flowderived$23,730,000N/M
Free Cash Flowderived$14,063,000N/M
Margins · derived
Gross margin69.0%+0.8 pt vs Q4 2023
Operating margin-5.3%+3.8 pt vs Q4 2023
Net margin-13.5%−2.5 pt vs Q4 2023

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$215.66M$200.42M$122.23M$125.06M
Net Income-$29.15M-$22.17M-$7.06M-$32.81M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR